Capital Asset Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
VCM
VPM
Capital Asset Advisory Services's VRTX Position: Q1 2026 in Review
Capital Asset Advisory Services reduced its Vertex Pharmaceuticals (VRTX) stake by 10% in Q1 2026, selling an estimated $27K and leaving 507 shares worth $223K. The position accounts for 0.01% of the portfolio, ranked #274.
Capital Asset Advisory Services first reported a position in VRTX in Q4 2020 and has held it in 5 quarters since. The position peaked at $265K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Capital Asset Advisory Services held 507 shares of Vertex Pharmaceuticals worth $223K as of Q1 2026.
- Capital Asset Advisory Services sold 58 Vertex Pharmaceuticals shares in Q1 2026, an estimated $27K.
- Vertex Pharmaceuticals made up 0.01% of Capital Asset Advisory Services's portfolio in Q1 2026, its #274 holding.
- Capital Asset Advisory Services first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 5 quarters since.
- Capital Asset Advisory Services's Vertex Pharmaceuticals position peaked at $265K in Q4 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Capital Asset Advisory Services's 13F filing for Q1 2026, filed 24 Apr 2026.